Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174096 | 0.76 | BTN3A1 (0.40) | ALDH1A1BTN3A1TSHRCYP3A4 | |
| Benzene SCHEMBL11408934 | 0.74 | TSHR (0.43) | ALDH1A1BTN3A1TSHRCYP3A4CYP2C19 | |
| SCHEMBL10625461 | 0.74 | BTN3A1 (0.39) | BTN3A1TSHRCYP3A4 | |
| Ammonia Solution, Strong SCHEMBL8023938 | 0.74 | BTN3A1 (0.39) | BTN3A1TSHRCYP3A4 | |
| SCHEMBL11677557 | 0.74 | BTN3A1 (0.39) | BTN3A1TSHRCYP3A4 | |
| SCHEMBL366766 | 0.71 | PPARD (0.39) | BTN3A1TSHR | |
| Benzyl Bromide SCHEMBL19949806 | 0.71 | TSHR (0.51) | ALDH1A1BTN3A1TSHRCYP3A4 | |
| SCHEMBL28486412 | 0.70 | CYP3A4 (0.60) | ALDH1A1KMT2ALMNATSHRMEN1 | |
| Ammonia Solution, Strong SCHEMBL790445 | 0.70 | PPARD (0.38) | BTN3A1TSHR | |
| Phosphonic Acid SCHEMBL10534004 | 0.69 | BTN3A1 (0.35) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510035-B1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | PROMEGA CORP (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | PROMEGA CORPORATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | SI, GLB1, CTRL | ALDH1A1 3380/4885BTN3A1 4629/4885KMT2A 3495/4885 |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | SI, GLB1, PREP | ALDH1A1 3920/4885BTN3A1 4394/4885KMT2A 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.